Wall Street analyst estimates for GH Research PLC (GHRS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD).
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.27 | ||
| 2026-08-06 | $-0.23 | $-0.29 | +19.6% |
| 2026-05-14 | $-0.31 | $-0.27 | -14.8% |
| 2026-03-05 | $-0.23 | $-0.29 | +20.7% |
| 2025-11-06 | $-0.23 | $-0.23 | +0.0% |
| 2025-08-07 | $-0.15 | $-0.22 | +31.8% |
| 2025-05-08 | $-0.19 | $-0.61 | +68.9% |
| 2025-02-27 | $-0.17 | $-0.23 | +26.1% |
Valuation Ratios
| Price / Book | 5.14 |
| EV / EBITDA | -25.02 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | $335000 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | -$335000 |
| Research & Development | $296000 | $338000 | $8.6M | $20.5M | $29.8M | $35.0M | $38.7M |
| Selling, General & Admin | $14000 | $108000 | $6.5M | $10.1M | $11.1M | $15.0M | $21.6M |
| Operating Expenses | $310000 | $446000 | $15.1M | $30.6M | $41.2M | $50.3M | $60.3M |
| Operating Income | -$310000 | -$446000 | -$15.1M | -$30.6M | -$41.2M | -$50.3M | -$60.7M |
| EBITDA | 0 | 0 | -$9.2M | -$22.4M | -$35.2M | -$38.6M | -$47.5M |
| Interest Expense | 0 | 0 | $9000 | $723000 | $717000 | $462999 | |
| Pre-tax Income | -$310000 | -$446000 | -$9.2M | -$22.5M | -$35.6M | -$39.0M | -$48.3M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$310000 | -$446000 | -$9.2M | -$22.5M | -$35.6M | -$39.0M | -$48.3M |
| EPS | $-0.01 | $-0.01 | $-0.18 | $-0.14 | $-0.68 | $-0.75 | $-0.79 |
| EPS (Diluted) | $-0.01 | $-0.01 | $-0.18 | $-0.14 | $-0.68 | $-0.75 | $-0.79 |
| Shares Outstanding (Diluted) | $28.0M | $30.4M | $52.0M | $52.0M | $52.0M | $52.0M | $61.0M |
Price
| Price | $27.75 |
| Market Cap | $1.9B |
| Exchange | NASDAQ |
| Country | IE |
Related companies: ABUS · KURA · LENZ · NBTX · PROK · PVLA · RZLT
Explore sector: Healthcare · Biotechnology
More sections of GHRS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks